Stockholm - Delayed Quote SEK

Stayble Therapeutics AB (publ) (STABL.ST)

Compare
0.7200 -0.0250 (-3.36%)
At close: 5:29 PM GMT+1
Loading Chart for STABL.ST
DELL
  • Previous Close 0.7450
  • Open 0.7300
  • Bid 0.6850 x --
  • Ask 0.7150 x --
  • Day's Range 0.6800 - 0.7700
  • 52 Week Range 0.1900 - 4.9400
  • Volume 352,463
  • Avg. Volume 540,261
  • Market Cap (intraday) 31.479M
  • Beta (5Y Monthly) 0.26
  • PE Ratio (TTM) --
  • EPS (TTM) -1.0100
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Stayble Therapeutics AB (publ) develops injectable treatment for chronic pain triggered by disc degeneration. The company develops STA363, an injection into the disc that targets chronic low back and leg pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.

www.staybletherapeutics.se

2

Full Time Employees

December 31

Fiscal Year Ends

Recent News: STABL.ST

View More

Performance Overview: STABL.ST

Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

STABL.ST
137.62%
OMX Stockholm 30 Index
6.46%

1-Year Return

STABL.ST
86.42%
OMX Stockholm 30 Index
20.05%

3-Year Return

STABL.ST
89.28%
OMX Stockholm 30 Index
9.82%

5-Year Return

STABL.ST
89.69%
OMX Stockholm 30 Index
65.53%

Compare To: STABL.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: STABL.ST

View More

Valuation Measures

Annual
As of 11/5/2024
  • Market Cap

    32.57M

  • Enterprise Value

    24.51M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.67

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -52.64%

  • Return on Equity (ttm)

    -97.00%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -20.4M

  • Diluted EPS (ttm)

    -1.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.06M

  • Total Debt/Equity (mrq)

    6.96%

  • Levered Free Cash Flow (ttm)

    -13.07M

Research Analysis: STABL.ST

View More

Company Insights: STABL.ST

Research Reports: STABL.ST

View More

People Also Watch